Market Announcement



18 January 2022

HeraMed Limited (ASX: HMD) – Trading Halt

Description

The securities of HeraMed Limited ('HMD') will be placed in trading halt at the request of HMD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 20 January 2022 or when the announcement is released to the market.

Issued by

Barbara Lim Adviser, Listings Compliance (Perth)



ASX ANNOUNCEMENT

18 January 2022

Barbara Lim ASX Operations Level 40 Central Park 152-158 St George's Terrace PERTH WA 6000

Via Email: tradinghaltsperth@asx.com.au

Dear Barbara

TRADING HALT REQUEST

Medical technology company, **HeraMED Limited (ASX:HMD)** ("HeraMED" or the "Company") requests that the securities of the Company be placed into a trading halt of up to two trading days with immediate effect.

For the purposes of ASX Listing Rule 17.1 and in support of its request, the Company advises that:

- 1. The trading halt is requested pending an announcement by the Company regarding an Australian based commercial licence agreement for the roll-out of the HeraCARE solution.
- 2. The Company requests that the trading halt remains in place until the earlier of the Company releasing an announcement regarding the commercial agreement or prior to the commencement of trading on Thursday, 20 January 2022.
- 3. The Company is not aware of any reason why the request for the trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Your faithfully

Jonathan Hart Company Secretary

-ENDS-